BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

977 related articles for article (PubMed ID: 31560893)

  • 1. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
    Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
    Gastroenterology; 2019 Dec; 157(6):1630-1645.e6. PubMed ID: 31560893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
    Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
    Gastroenterology; 2020 May; ():. PubMed ID: 32428506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents.
    Gao Q; Wang ZC; Duan M; Lin YH; Zhou XY; Worthley DL; Wang XY; Niu G; Xia Y; Deng M; Liu LZ; Shi JY; Yang LX; Zhang S; Ding ZB; Zhou J; Liang CM; Cao Y; Xiong L; Xi R; Shi YY; Fan J
    Gastroenterology; 2017 Jan; 152(1):232-242.e4. PubMed ID: 27639803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma Cell Polarization to the Immunoglobulin G Phenotype in Hepatocellular Carcinomas Involves Epigenetic Alterations and Promotes Hepatoma Progression in Mice.
    Wei Y; Lao XM; Xiao X; Wang XY; Wu ZJ; Zeng QH; Wu CY; Wu RQ; Chen ZX; Zheng L; Li B; Kuang DM
    Gastroenterology; 2019 May; 156(6):1890-1904.e16. PubMed ID: 30711627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 R249S mutation in hepatic organoids captures the predisposing cancer risk.
    Lam YK; Yu J; Huang H; Ding X; Wong AM; Leung HH; Chan AW; Ng KK; Xu M; Wang X; Wong N
    Hepatology; 2023 Sep; 78(3):727-740. PubMed ID: 36221953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma.
    Zhang W; He H; Zang M; Wu Q; Zhao H; Lu LL; Ma P; Zheng H; Wang N; Zhang Y; He S; Chen X; Wu Z; Wang X; Cai J; Liu Z; Sun Z; Zeng YX; Qu C; Jiao Y
    Gastroenterology; 2017 Jul; 153(1):249-262.e2. PubMed ID: 28363643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
    Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
    World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic and epigenetic changes in fibrosis-associated hepatocarcinogenesis in mice.
    Chappell G; Kutanzi K; Uehara T; Tryndyak V; Hong HH; Hoenerhoff M; Beland FA; Rusyn I; Pogribny IP
    Int J Cancer; 2014 Jun; 134(12):2778-88. PubMed ID: 24242335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulator of Calcineurin 1 Gene Isoform 4, Down-regulated in Hepatocellular Carcinoma, Prevents Proliferation, Migration, and Invasive Activity of Cancer Cells and Metastasis of Orthotopic Tumors by Inhibiting Nuclear Translocation of NFAT1.
    Jin H; Wang C; Jin G; Ruan H; Gu D; Wei L; Wang H; Wang N; Arunachalam E; Zhang Y; Deng X; Yang C; Xiong Y; Feng H; Yao M; Fang J; Gu J; Cong W; Qin W
    Gastroenterology; 2017 Sep; 153(3):799-811.e33. PubMed ID: 28583823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia.
    Gouas DA; Villar S; Ortiz-Cuaran S; Legros P; Ferro G; Kirk GD; Lesi OA; Mendy M; Bah E; Friesen MD; Groopman J; Chemin I; Hainaut P
    Carcinogenesis; 2012 Jun; 33(6):1219-24. PubMed ID: 22759751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variable Intra-Tumor Genomic Heterogeneity of Multiple Lesions in Patients With Hepatocellular Carcinoma.
    Xue R; Li R; Guo H; Guo L; Su Z; Ni X; Qi L; Zhang T; Li Q; Zhang Z; Xie XS; Bai F; Zhang N
    Gastroenterology; 2016 Apr; 150(4):998-1008. PubMed ID: 26752112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression.
    Midorikawa Y; Yamamoto S; Tatsuno K; Renard-Guillet C; Tsuji S; Hayashi A; Ueda H; Fukuda S; Fujita T; Katoh H; Ishikawa S; Covington KR; Creighton CJ; Sugitani M; Wheeler DA; Shibata T; Nagae G; Takayama T; Aburatani H
    Cancer Res; 2020 Sep; 80(18):3810-3819. PubMed ID: 32641413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 R249S mutation detected in circulating tumour DNA is associated with Prognosis of hepatocellular carcinoma patients with or without hepatectomy.
    Shen T; Li SF; Wang JL; Zhang T; Zhang S; Chen HT; Xiao QY; Ren WH; Liu C; Peng B; Ji XN; Yang Y; Lu PX; Chen TY; Yu L; Ji Y; Jiang DK
    Liver Int; 2020 Nov; 40(11):2834-2847. PubMed ID: 32594568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of genetic aberrations linked to tumorigenesis in regenerative nodules of liver cirrhosis.
    Kim SK; Takeda H; Takai A; Matsumoto T; Kakiuchi N; Yokoyama A; Yoshida K; Kaido T; Uemoto S; Minamiguchi S; Haga H; Shiraishi Y; Miyano S; Seno H; Ogawa S; Marusawa H
    J Gastroenterol; 2019 Jul; 54(7):628-640. PubMed ID: 30756187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aberrant methylation of multiple genes and its clinical implication in hepatocellular carcinoma].
    Lou C; Yang B; Gao YT; Wang YJ; Nie FH; Yuan Q; Zhang CL; Du Z
    Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):831-6. PubMed ID: 19173828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneity.
    Shi JY; Xing Q; Duan M; Wang ZC; Yang LX; Zhao YJ; Wang XY; Liu Y; Deng M; Ding ZB; Ke AW; Zhou J; Fan J; Cao Y; Wang J; Xi R; Gao Q
    Oncotarget; 2016 Jan; 7(3):2867-77. PubMed ID: 26672766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence.
    Zhou SL; Zhou ZJ; Hu ZQ; Song CL; Luo YJ; Luo CB; Xin HY; Yang XR; Shi YH; Wang Z; Huang XW; Cao Y; Fan J; Zhou J
    J Hepatol; 2019 Dec; 71(6):1152-1163. PubMed ID: 31349001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.
    Lin XM; Hu L; Gu J; Wang RY; Li L; Tang J; Zhang BH; Yan XZ; Zhu YJ; Hu CL; Zhou WP; Li S; Liu JF; Gonzalez FJ; Wu MC; Wang HY; Chen L
    Gastroenterology; 2017 Apr; 152(5):1187-1202. PubMed ID: 28065789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3.
    Wei L; Chiu DK; Tsang FH; Law CT; Cheng CL; Au SL; Lee JM; Wong CC; Ng IO; Wong CM
    J Hepatol; 2017 Oct; 67(4):758-769. PubMed ID: 28532996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.